Relx (LON:REL)‘s stock had its “overweight” rating reiterated by investment analysts at JPMorgan Chase & Co. in a report issued on Monday, ThisIsMoney.Co.Uk reports.

Other research analysts have also issued research reports about the stock. Liberum Capital reissued a “buy” rating on shares of Relx in a research report on Thursday, February 21st. Goldman Sachs Group decreased their price objective on Relx from GBX 2,167 ($28.32) to GBX 2,123 ($27.74) and set a “buy” rating on the stock in a report on Tuesday, February 26th. Numis Securities reiterated a “hold” rating and issued a GBX 1,585 ($20.71) price objective on shares of Relx in a research note on Thursday, February 21st. Kepler Capital Markets lowered their price objective on Relx from GBX 1,900 ($24.83) to GBX 1,780 ($23.26) and set a “buy” rating on the stock in a research note on Thursday, January 10th. Finally, Berenberg Bank reissued a “buy” rating and issued a GBX 1,850 ($24.17) target price on shares of Relx in a report on Monday, March 4th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. Relx presently has an average rating of “Buy” and a consensus price target of GBX 1,788.08 ($23.36).

Shares of Relx stock opened at GBX 1,650.50 ($21.57) on Monday. The stock has a market cap of $32.21 billion and a PE ratio of 23.12. Relx has a twelve month low of GBX 1,459 ($19.06) and a twelve month high of GBX 1,781.50 ($23.28). The company has a current ratio of 0.44, a quick ratio of 0.36 and a debt-to-equity ratio of 270.50.

In related news, insider Erik Engstrom sold 36,334 shares of Relx stock in a transaction dated Friday, February 22nd. The shares were sold at an average price of GBX 1,770 ($23.13), for a total transaction of £643,111.80 ($840,339.47).

About Relx

RELX PLC provides information and analytics for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals.

Recommended Story: Outstanding Shares and The Effect on Share Price

Analyst Recommendations for Relx (LON:REL)

Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.